QCLS Q/C TECHNOLOGIES, INC.
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1321834 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-120.7%
TTM EPS YoY105.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-113.0%
ROA-58.8%
ROIC (approx.)-131.5%
Asset turnover—
Leverage & solvency
Liabilities / assets10.2%
Debt / equity0.00x
Current ratio5.06x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.57x
Accruals ratio-25.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $3.47M | $3.44M | $7.87M | $9.07M | $6.75M |
| SG&A expense | $3.74M | $4.16M | $5.44M | $5.52M | $6.42M |
| Operating income | -$9.85M | -$10.17M | -$17.12M | -$15.28M | -$28.81M |
| Pretax income | -$11.63M | -$23.36M | -$4.00M | -$15.20M | -$29.89M |
| Net income | -$11.63M | -$23.36M | -$4.00M | -$15.20M | -$29.89M |
| EPS (basic) | -8.66 | -1,080.87 | -5.33 | -11.74 | -0.85 |
| EPS (diluted) | -8.66 | -1,080.87 | -5.33 | -11.74 | — |
| Weighted avg. shares (diluted) | 1.73M | 25,129 | 1.54M | 1.29M | 35.02M |
| Balance sheet | |||||
| Cash & equivalents | $986,996 | $173,154 | $2.68M | $749,090 | $555,967 |
| Short-term investments | $14.80M | $8.35M | $2.24M | $4.09M | $11.00M |
| Current assets | $16.58M | $9.41M | $5.82M | $5.40M | $12.67M |
| Goodwill | $10.50M | $10.50M | $10.50M | $10.50M | $10.50M |
| Intangibles | $14.09M | — | — | — | — |
| Total assets | $41.17M | $21.42M | $17.86M | $17.54M | $24.81M |
| Current liabilities | $5.53M | $6.70M | $4.99M | $2.77M | $1.04M |
| Total liabilities | $16.44M | $6.70M | $5.09M | $2.84M | $1.17M |
| Shareholders' equity | $21.75M | $9.79M | $12.37M | $14.70M | $23.65M |
| Shares outstanding | 7.69M | 33,636 | 2.02M | 1.32M | 37.67M |
| Cash flow statement | |||||
| Operating cash flow | -$9.07M | -$8.98M | -$12.98M | -$12.27M | -$19.52M |
| Capital expenditure | $1.75M | — | — | — | — |
| Free cash flow | -$10.82M | — | — | — | — |
| Investing cash flow | -$8.42M | -$6.10M | $1.85M | $6.91M | $19.85M |
| Financing cash flow | $18.30M | $12.57M | $13.07M | $5.55M | $73,533 |
| Stock-based compensation | $2.17M | $1.06M | $3.05M | $695,191 | $90,002 |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.